Effect of tadalafil on anaerobic performance indices in healthy athletes

被引:14
作者
Guidetti, L. [1 ]
Emerenziani, G. P. [1 ]
Gallotta, M. C. [1 ]
Pigozzi, F. [1 ]
Di Luigi, L. [1 ]
Baldari, C. [1 ]
机构
[1] Univ IUSM, Dept Hlth Sci, Rome, Italy
关键词
D O I
10.1136/bjsm.2007.037630
中图分类号
G8 [体育];
学科分类号
04 ; 0403 ;
摘要
Objective: Given the therapeutic and non-therapeutic use of the tadalafil, (phosphodiesterase-5 inhibitor, PDE-5i), we examined its effects on anaerobic performance indices. Methods: In total, 12 well-trained subjects reported to the laboratory on two occasions 1 week apart to perform a 30 s Wingate anaerobic power test (WAnT) on a bicycle ergometer. The day before the WAnT, the subjects were double-blinded to receive an oral dose of tadalafil (20 mg) or placebo. Blood lactate value at rest and 1, 3, 6 and 10 minutes of recovery phase, mean power, peak power, time to peak power and fatigue index were assessed for each WAnT. Results: Blood lactate values at the 3-min recovery WAnT increased significantly in the tadalafil condition (mean (SD) 13.9 (1.7) v 12.8 (1.3) mmol/l; p < 0.05) and time to peak power decreased significantly (6.3 (1.3) v 5.7 (1.5) s; p = 0.05). No differences were observed in any other parameters between the two conditions. Conclusion: The primary finding of this investigation was that the administration of a single dose of a long-term PDE-5i does not substantially influence anaerobic performance indices. However, results demonstrated both an increase in lactate values at the 3-min point of the recovery phase and a decrease in time to peak power.
引用
收藏
页码:130 / 133
页数:4
相关论文
共 30 条
[21]   Cardiovascular effects of tadalafil in patients on common anti hypertensive therapies [J].
Kloner, RA ;
Mitchell, M ;
Emmick, JT .
AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (9A) :47M-57M
[22]   3′,5′-Cyclic nucleotide phosphodiesterase 11A:: localization in human tissues [J].
Loughney, K ;
Taylor, J ;
Florio, VA .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2005, 17 (04) :320-325
[23]  
MCARDLE W, 1996, EXERCISE PHYSL, P101
[24]  
McCullough AR, 2003, J ANDROL, V24, pS52
[25]   ASSESSMENT OF PEAK OXYGEN-CONSUMPTION, LACTATE AND VENTILATORY THRESHOLDS AND CORRELATION WITH RESTING AND EXERCISE HEMODYNAMIC DATA IN CHRONIC CONGESTIVE HEART-FAILURE [J].
METRA, M ;
RADDINO, R ;
CAS, LD ;
VISIOLI, O .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 65 (16) :1127-1133
[26]   Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension [J].
Michelakis, ED ;
Tymchak, W ;
Noga, M ;
Webster, L ;
Wu, XC ;
Lien, D ;
Wang, SH ;
Modry, D ;
Archer, SL .
CIRCULATION, 2003, 108 (17) :2066-2069
[27]   The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial [J].
Porst, H ;
Rosen, R ;
Padma-Nathan, H ;
Goldstein, I ;
Giuliano, F ;
Ulbrich, E ;
Bandel, T .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2001, 13 (04) :192-199
[28]   Effects of sildenafil on the human response to acute hypoxia and exercise [J].
Ricart, A ;
Maristany, J ;
Fort, N ;
Leal, C ;
Pagés, T ;
Viscor, G .
HIGH ALTITUDE MEDICINE & BIOLOGY, 2005, 6 (01) :43-49
[29]   Recreational use and misuse of phosphodiesterase 5 inhibitors [J].
Smith, KM ;
Romanelli, F .
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2005, 45 (01) :63-75
[30]  
Traverse JH, 2000, CIRCULATION, V102, P2997